# Infographic


Summary of results for people diagnosed with oesophageal or gastric (OG) cancer in England and Wales between 1 Jan 2022 and 31 Dec 2023



England: 19,243

Wales: 1,339

# Patient profile at diagnosis




people diagnosed with OG cancer

# **Emergency admission & stage 4 diagnoses**












People diagnosed with emergency admission stage 4 disease



People aged 80 years and over had the highest rates of diagnosis via emergency admission

# Waiting times

Time from diagnostic endoscopy to start of disease-targeted treatment\*



### **Curative treatment & outcomes**

% people diagnosed at stage 1-3 treated receiving curative treatment

# Survival following surgical resection\*\*



# Access to CNS



Where data were complete\*\*\*, 93% of people in England were seen by a CNS\*\*\*\*



People diagnosed by emergency admission, and those with survival of less than 90 days after diagnosis, were less likely to see a CNS

## Non-curative treatment & outcomes



% people diagnosed at stage 4 treated with SACT and/or radiotherapy





died within 30 days of starting SACT in England \*\*\*\*\*

died within 90 days of starting SACT in England \*\*\*\*\*

CNS: Clinical Nurse Specialist

Gast. cancer: Gastric (stomach) cancer

OG: Oesophago-Gastric

Oes SCC: Oesophageal squamous cell carcinoma

Oes ACA: Oesophageal adenocarcinoma

tx: Treatment

SACT: Systemic Anti-Cancer Therapy

- \* Waiting times measured from date of first endoscopy within 30 days of date of diagnosis and date of first disease-targeted treatment of EMR/ESD, surgery, radiotherapy, or SACT.
- \*\* 3 years' of data (1 Jan 2021 31 Dec 2023) used for surgical outcomes to ensure enough procedures to produce robust statistics; results are the % for people undergoing surgery
- \*\*\* Data available for only 63% of patients.
- \*\*\*\* CNS data not available for Wales.
- \*\*\*\*\* Outcomes of palliative chemotherapy are not reported for Wales due to known issues with oncology data.